Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
There are some existing and planned industry sponsored studies comparing the addition of different second line drugs alongside lamotrigine (lamictal), carbamazepine, or valproate. This practice article asks what should be done in light of the current uncertainty over treatment.
Other recent education:
The Netherlands has Europe’s best healthcare system, concludes the latest Euro Health Consumer Index, which is based on indicators such as patients’ rights and waiting times.
Other news published on 17 November:
According to this systematic review and meta-analysis, soluble fibre, antispasmodics, and peppermint oil were all more effective than placebo in the treatment of irritable bowel syndrome. It may be a little premature to follow the authors’ recommendation that national guidelines should be updated to include therapeutic guidance on these agents, but the results should reawaken an interest in the pharmacotherapy of irritable bowel syndrome and stimulate further research, says an accompanying editorial.
Other recent research:
The JUPITER randomised controlled trial is seen by many as opening the door to new avenues to prevention, but despite the hype surrounding the study, no change in strategy is needed, concludes this editorial.(Picture credit: SPL)
Other recent comment:
Is medicine simply a "young person's game?" The latest Career Focus looks at the evidence for performance in doctors over the age of 65. Also, the current BMJ print issue contains four research papers and an editorial on doctors' health to coincide with an international conference taking place in London this week. In an accompanying podcast, a doctor describes the steps she took to tackle alcohol dependency.